You can find interesting research projects below. 
Fill out the form below to add yourself and your research project to this page. This page may take 24 hours to update.


Primary Investigator: Torbjørn Omland
Submission date: 18/08/2021
Primary Prosessional interest: cardiology
Organization Country: Norway
Looking for collaboration on: future project
Contact Name: Geeta Gulati
Contact Email:

Brief Summary: Anthracycline- and trastuzumab-associated cardiotoxicity may lead to a halt in breast cancer treatment. Neurohormonal blockade may prevent the cardiotoxicity, but studies have been inconclusive. The novel heart failure drug sacubitril/valsartan has not been tested in a cardio-oncology setting. PRADAII is a randomized, placebo-controlled, double-blind, multi-center, investigator-initiated trial designed to assess if sacubitril/valsartan given concomitantly in (neo)adjuvant breast cancer treatment including anthracyclines ± trastuzumab, may prevent cardiotoxicity. Patients will be examined with cardiovascular magnetic resonance (CMR), echocardiography, circulating cardiovascular biomarkers and functional testing. Primary outcome is change in left ventricular ejection fraction by CMR after 18 months. NCT03760588.

Primary Investigator: Marie Louise Milo
Submission date: 12/10/2021
Primary Prosessional interest: oncology
Organization Country: Denmark
Looking for collaboration on: future project
Contact Name: Marie Louise Milo
Contact Email:

Brief Summary: The aim of this study was to report individual radiation (RT) doses to the cardiac substructures for patients treated for early breast cancer with CT-based RT. In total, 204 cases and 408 controls were identified with 7.3 years follow-up. The delivered RT doses to cardiac substructures depended on laterality of RT, however, no difference in the localization of coronary artery disease (CAD) in left-sided and right-sided cases was detected. For the controls, no difference in the RT doses to the heart and cardiac substructures was observed compared to the cases. Thus, RT doses to the heart and cardiac substructures in the range as observed in this study, indicated no trend towards a dose-response relationship between RT dose and CAD during a median follow-up at 7.3 years.